Baseline characteristics in REPRIEVE with WES
| . | Overall (N = 4486) . |
|---|---|
| Age, mean (SD) | 49.9 (6.38) |
| Natal sex | |
| Female | 1650 (36.8%) |
| Male | 2836 (63.2%) |
| Ethnicity (collected in North America only) | |
| Not in North America | 2608 (58.1%) |
| Hispanic or Latino | 353 (7.9%) |
| Not Hispanic or Latino | 1508 (33.6%) |
| Unknown | 17 (0.4%) |
| Race | |
| Asian | 1050 (23.4%) |
| Black or African American | 2089 (46.6%) |
| Other | 279 (6.2%) |
| White | 1068 (23.8%) |
| Country of recruitment | |
| Botswana | 277 (6.2%) |
| Brazil | 231 (5.1%) |
| Haiti | 140 (3.1%) |
| India | 447 (10.0%) |
| Peru | 146 (3.3%) |
| South Africa | 475 (10.6%) |
| Thailand | 587 (13.1%) |
| Uganda | 180 (4.0%) |
| United States/Canada | 1878 (41.9%) |
| Zimbabwe | 125 (2.8%) |
| Body mass index, median (IQR) | 25.3 (22.2-29.0) |
| Smoking status | |
| Current | 980 (21.8%) |
| Former | 964 (21.5%) |
| Never | 2537 (56.6%) |
| Entry CD4 level (cells per mm3), mean (SD) | 654 (291) |
| ART duration, mean (SD), y | 3.68 (3.52) |
| Baseline ART regimen (by class) | |
| NRTI + INSTI | 896 (20.0%) |
| NRTI + NNRTI | 2510 (56.0%) |
| NRTI + PI | 781 (17.4%) |
| NRTI-sparing | 93 (2.1%) |
| Other NRTI-containing | 206 (4.6%) |
| eGFR (mL/min per 1.73 m2), mean (SD) | 99.1 (19.2) |
| On diabetic medications | 13 (0.3%) |
| History of hypertension | 1495 (33.3%) |
| Family history of CVD | 673 (15.0%) |
| 10-y ASCVD risk score (%) | |
| Median (IQR) | 3.90 (1.70-6.60) |
| Total cholesterol (mg/dL) | |
| Mean (SD) | 185 (36.3) |
| HDL cholesterol (mg/dL) | |
| Mean (SD) | 51.5 (16.9) |
| LDL cholesterol (mg/dL) | |
| Mean (SD) | 107 (30.9) |
| Triglycerides (mg/dL) | |
| Median (IQR) | 108 (78.0-159) |
| Non-HDL cholesterol (mg/dL) | |
| Mean (SD) | 133 (35.2) |
| . | Overall (N = 4486) . |
|---|---|
| Age, mean (SD) | 49.9 (6.38) |
| Natal sex | |
| Female | 1650 (36.8%) |
| Male | 2836 (63.2%) |
| Ethnicity (collected in North America only) | |
| Not in North America | 2608 (58.1%) |
| Hispanic or Latino | 353 (7.9%) |
| Not Hispanic or Latino | 1508 (33.6%) |
| Unknown | 17 (0.4%) |
| Race | |
| Asian | 1050 (23.4%) |
| Black or African American | 2089 (46.6%) |
| Other | 279 (6.2%) |
| White | 1068 (23.8%) |
| Country of recruitment | |
| Botswana | 277 (6.2%) |
| Brazil | 231 (5.1%) |
| Haiti | 140 (3.1%) |
| India | 447 (10.0%) |
| Peru | 146 (3.3%) |
| South Africa | 475 (10.6%) |
| Thailand | 587 (13.1%) |
| Uganda | 180 (4.0%) |
| United States/Canada | 1878 (41.9%) |
| Zimbabwe | 125 (2.8%) |
| Body mass index, median (IQR) | 25.3 (22.2-29.0) |
| Smoking status | |
| Current | 980 (21.8%) |
| Former | 964 (21.5%) |
| Never | 2537 (56.6%) |
| Entry CD4 level (cells per mm3), mean (SD) | 654 (291) |
| ART duration, mean (SD), y | 3.68 (3.52) |
| Baseline ART regimen (by class) | |
| NRTI + INSTI | 896 (20.0%) |
| NRTI + NNRTI | 2510 (56.0%) |
| NRTI + PI | 781 (17.4%) |
| NRTI-sparing | 93 (2.1%) |
| Other NRTI-containing | 206 (4.6%) |
| eGFR (mL/min per 1.73 m2), mean (SD) | 99.1 (19.2) |
| On diabetic medications | 13 (0.3%) |
| History of hypertension | 1495 (33.3%) |
| Family history of CVD | 673 (15.0%) |
| 10-y ASCVD risk score (%) | |
| Median (IQR) | 3.90 (1.70-6.60) |
| Total cholesterol (mg/dL) | |
| Mean (SD) | 185 (36.3) |
| HDL cholesterol (mg/dL) | |
| Mean (SD) | 51.5 (16.9) |
| LDL cholesterol (mg/dL) | |
| Mean (SD) | 107 (30.9) |
| Triglycerides (mg/dL) | |
| Median (IQR) | 108 (78.0-159) |
| Non-HDL cholesterol (mg/dL) | |
| Mean (SD) | 133 (35.2) |
ART, antiretroviral therapy; CVD, cardiovascular disease; CD4, cluster of differentiation 4; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; hsCRP, high sensitivity C reactive protein; LDL, low density lipoprotein; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.